Ушбу иш иқтибос қилган ишлар

59 та иш

Иш: Relationship between severe acute respiratory syndrome coronavirus 2 and diabetes mellitus (review)

1. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

   Fei Zhou, Ting Yu, Ronghui Du +16

   Мақола202012 иқтибос

   ABIABI:AkademIndex/openalex/2026.other.042529

2. Endothelial cell infection and endotheliitis in COVID-19

   Zsuzsanna Varga, Andreas J. Flammer, Peter Steiger +7

   Бошқа20207 иқтибос

   ABIABI:AkademIndex/openalex/2026.other.581199

3. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor

   Markus Hoffmann, Hannah Kleine‐Weber, Simon Schroeder +10

   Мақола20206 иқтибос

   ABIABI:AkademIndex/openalex/2026.other.508188

4. Type 2 diabetes as an inflammatory disease

   Marc Y. Donath, Steven E. Shoelson

   Шарҳ мақола20115 иқтибос

   ABIABI:AkademIndex/openalex/2026.other.570547

5. The trinity of COVID-19: immunity, inflammation and intervention

   Matthew Zirui Tay, Chek Meng Poh, Laurent Rénia +2

   Шарҳ мақола20204 иқтибос

   ABIABI:AkademIndex/openalex/2026.other.204770

6. Neutrophil extracellular traps in COVID-19

   Yu Zuo, Srilakshmi Yalavarthi, Hui Shi +10

   Мақола20203 иқтибос

   ABIABI:AkademIndex/openalex/2026.other.210933

7. Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection?

   Lei Fang, George Karakiulakis, Michael Roth

   Бошқа20203 иқтибос

   ABIABI:AkademIndex/openalex/2026.other.219226

8. Continuation versus discontinuation of renin–angiotensin system inhibitors in patients admitted to hospital with COVID-19: a prospective, randomised, open-label trial

   Jordana B. Cohen, Thomas C. Hanff, Preethi William +30

   Мақола20212 иқтибос

   ABIABI:AkademIndex/openalex/2026.other.225813

9. Cytokine release syndrome in severe COVID-19: interleukin-6 receptor antagonist tocilizumab may be the key to reduce mortality

   Chi Zhang, Zhao Wu, Jiawen Li +2

   Мақола20202 иқтибос

   ABIABI:AkademIndex/openalex/2026.other.551572

10. Diabetes is a risk factor for the progression and prognosis of <scp>COVID</scp>‐19

    Weina Guo, Mingyue Li, Yalan Dong +11

    Мақола20202 иқтибос

    ABIABI:AkademIndex/openalex/2026.other.581192

11. Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy

    Ning Tang, Huan Bai, Xing Chen +3

    Мақола20202 иқтибос

    ABIABI:AkademIndex/openalex/2026.other.581193

12. COVID-19, diabetes mellitus and ACE2: The conundrum

    Rimesh Pal, Anil Bhansali

    Бошқа20202 иқтибос

    ABIABI:AkademIndex/openalex/2026.other.581195

13. Glycemic Characteristics and Clinical Outcomes of COVID-19 Patients Hospitalized in the United States

    Bruce W. Bode, Valerie Garrett, Jordan Messler +4

    Мақола20202 иқтибос

    ABIABI:AkademIndex/openalex/2026.other.581201

14. Сарлавҳасиз

    Бошқа1 иқтибос

    ABIABI:AkademIndex/openalex/2026.other.581160

15. Сарлавҳасиз

    Бошқа1 иқтибос

    ABIABI:AkademIndex/openalex/2026.other.581161

16. Сарлавҳасиз

    Бошқа1 иқтибос

    ABIABI:AkademIndex/openalex/2026.other.581162

17. Сарлавҳасиз

    Бошқа1 иқтибос

    ABIABI:AkademIndex/openalex/2026.other.581163

18. Сарлавҳасиз

    Бошқа1 иқтибос

    ABIABI:AkademIndex/openalex/2026.other.581164

19. Сарлавҳасиз

    Бошқа1 иқтибос

    ABIABI:AkademIndex/openalex/2026.other.581165

20. Сарлавҳасиз

    Бошқа1 иқтибос

    ABIABI:AkademIndex/openalex/2026.other.581166

21. Сарлавҳасиз

    Бошқа1 иқтибос

    ABIABI:AkademIndex/openalex/2026.other.581167

22. Сарлавҳасиз

    Бошқа1 иқтибос

    ABIABI:AkademIndex/openalex/2026.other.581168

23. Сарлавҳасиз

    Бошқа1 иқтибос

    ABIABI:AkademIndex/openalex/2026.other.581169

24. Сарлавҳасиз

    Бошқа1 иқтибос

    ABIABI:AkademIndex/openalex/2026.other.581170

25. Сарлавҳасиз

    Бошқа1 иқтибос

    ABIABI:AkademIndex/openalex/2026.other.581171